Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deferred Tax Liability (2021 - 2024)

Prime Medicine (PRME) has disclosed Non-Current Deferred Tax Liability for 4 consecutive years, with $134000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Non-Current Deferred Tax Liability rose 74.03% year-over-year to $134000.0, compared with a TTM value of $134000.0 through Mar 2024, up 74.03%, and an annual FY2022 reading of $279000.0, down 77.55% over the prior year.
  • Non-Current Deferred Tax Liability was $134000.0 for Q1 2024 at Prime Medicine, up from $108000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $1.2 million in Q4 2021 and bottomed at $77000.0 in Q1 2023.
  • Average Non-Current Deferred Tax Liability over 4 years is $387000.0, with a median of $206500.0 recorded in 2022.
  • The sharpest move saw Non-Current Deferred Tax Liability crashed 77.55% in 2022, then soared 74.03% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at $1.2 million in 2021, then plummeted by 77.55% to $279000.0 in 2022, then tumbled by 61.29% to $108000.0 in 2023, then rose by 24.07% to $134000.0 in 2024.
  • Business Quant data shows Non-Current Deferred Tax Liability for PRME at $134000.0 in Q1 2024, $108000.0 in Q2 2023, and $77000.0 in Q1 2023.